Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.39B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.18M
Average 0.08M
Big Five Numbers
Nanobiotix S.A. growth analysis
Start with the long-run numbers that show whether NBTX compounds: return on capital and growth in sales, earnings, equity, and free cash flow.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | Not available | Not available | Not available | Not available |
Revenue | Not available | Not available | +83.8% | Not available |
Equity | Not available | Not available | Not available | Not available |
Cash | Not available | Not available | +8.4% | +6.1% |
ROIC | Not available | -177.6% | -213.0% | -74.3% |
Analysis
In the latest year, Cash was strongest at +6.1%, while ROIC was weakest at -74.3%. The three-year average ROIC was -213.0%, a measure of how efficiently the company earned that growth.
Growth analysis
Is growth accelerating or fading?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +83.8% | +37.6% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +83.8% over three years. Forward estimates point to Revenue at +37.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Revenue segments
Where does the growth come from?
Break revenue down by product and geography to see which parts of the business drive the trend.
Revenue by segment
Where NBTX earns its revenue, as reported in company filings
- Services
- Research And Development
- Other Sales
- Other Services
| Segment · FY2025 | Revenue | Share | YoY |
|---|---|---|---|
| Services | €22.68M | 43.3% | — |
| Research And Development | €21.8M | 41.6% | — |
| Other Sales | €6.96M | 13.3% | +17.5% |
| Other Services | €900K | 1.7% | — |
Figures in EUR. Segments account for 176.6% of reported FY2025 revenue; -€22.7M is not attributed to a segment.
Free cash flow
Does growth turn into cash?
Check whether reported growth converts into free cash flow after capital spending.
Free Cash Flow
Net Income to FCF bridge
FY2025
Analysis
FY2025 free cash flow is -$34.0M. FCF conversion is 141.8% of net income. Operating cash flow was -$33.4M, with capex of -$546.0K. The largest bridge item is Other Non-Cash at -$11.1M.
Price targets
What do analysts expect from the price?
Compare the current price with the low, average, and high analyst targets.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for NBTX.
Analyst ratings
How do analysts rate the stock?
Review the buy, hold, and sell split and recent upgrades and downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
Unlock analyst ratings
Sign in free to see the buy/hold/sell breakdown and recent rating changes for NBTX.
Competitor growth
How does Nanobiotix S.A. grow against peers?
Compare historical and forecast growth with similar companies.
Competitor Growth
Peer CAGR comparison & forward estimates
| Company | Market Cap | 10yr | 5yr | 3yr | Fwd |
|---|---|---|---|---|---|
ImmunityBio, Inc. IBRX | $6.40B | +85.4% | +184.8% | +678.6% | +86.0% (5yr)1 analysts |
Tyra Biosciences, Inc. TYRA | $1.38B | — | — | — | —5 analysts |
Syndax Pharmaceuticals, Inc. SNDX | $850.77M | +75.4% | +157.7% | — | +44.1% (5yr)5 analysts |
Kura Oncology, Inc. KURA | $713.90M | — | — | — | +66.5% (5yr)6 analysts |
Nuvectis Pharma, Inc. NVCT | $696.03M | — | — | — | —2 analysts |
ArriVent BioPharma, Inc. AVBP | $672.92M | — | — | — | —7 analysts |
Immix Biopharma, Inc. IMMX | $649.96M | — | — | — | —3 analysts |
Candel Therapeutics, Inc. CADL | $474.42M | — | — | — | —6 analysts |
Puma Biotechnology, Inc. PBYI | $401.70M | — | +0.3% | +0.0% | +0.2% (5yr)1 analysts |
Black Diamond Therapeutics, Inc. BDTX | $84.48M | — | — | — | +4.4% (5yr)5 analysts |
Questions
Growth questions
Common questions about NBTX's growth, answered from reported and forecast figures.
Is NBTX growing revenue?
Revenue grew 512.3% year over year, from -$7.19M to $29.64M.
Is NBTX turning growth into profit?
The latest net margin is -80.8%, which shows how much revenue became net income.
Continue the stock analysis
Jump to another research area for this company.